Stem Cell Therapies for Osteoarthritis Treatment

Osteoarthritis is a degenerative joint disorder marked by progressive cartilage loss, synovial inflammation and subchondral bone remodelling. Conventional management focuses on symptom relief via analgesics, physiotherapy and, ultimately, joint replacement. In recent years, stem cell-based interventions have emerged as potential disease-modifying therapies. These approaches harness mesenchymal stem cells (MSCs), which can be delivered autologously—from the patient’s own bone marrow aspirate concentrate (BMAC) or adipose-derived stromal vascular fraction (SVF)—or allogeneically, notably umbilical-cord-derived MSCs. Preclinical and early clinical data indicate that MSCs may exert anti-inflammatory and immunomodulatory effects, secrete trophic factors that support chondrogenesis and, under specific conditions, contribute directly to tissue repair. Delivery strategies range from simple intra-articular injection to scaffold-assisted implantation and combination with osteotomy to optimise load distribution. Across global centres, studies have explored optimal cell sources, dosages and processing methods, while monitoring safety, functional outcomes and imaging biomarkers. Although heterogeneity in protocols and mixed results temper enthusiasm, ongoing work continues to define the regenerative potential of stem cell therapies in delaying or obviating surgical intervention for osteoarthritis.

Research from Nature Portfolio

Recent clinical evidence has come from a multicentre phase 2/3 trial evaluating three cellular injections—autologous bone marrow aspirate concentrate, adipose stromal vascular fraction and umbilical-cord-derived mesenchymal stromal cells—against corticosteroid injection in patients with moderate to severe knee osteoarthritis. At 12 months, none of the stem cell–based treatments demonstrated superior pain relief or functional improvement over corticosteroids, nor did they differ significantly among themselves on clinical scores or imaging of cartilage status. Importantly, all interventions were well tolerated, with no serious adverse events attributable to the cell preparations. These findings underscore the necessity for rigorous comparative trials and standardised outcome measures when assessing orthobiologic therapies in osteoarthritis.

Stem Cell Therapies for Osteoarthritis Treatment publication trend

The graph below shows the total number of articles in stem cell therapies for osteoarthritis treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Mesenchymal stem cells (MSCs): Multipotent stromal cells capable of differentiating into cartilage, bone and fat cells, with immunomodulatory and trophic functions.

Bone marrow aspirate concentrate (BMAC): A minimally manipulated autologous bone marrow fraction enriched in MSCs, platelets and growth factors.

Stromal vascular fraction (SVF): A heterogeneous cell population isolated from adipose tissue containing MSCs, endothelial cells and immune cells.

Autologous: Derived from the same individual receiving the treatment, minimising immunogenic risk.

Allogeneic: Derived from a donor, enabling off-the-shelf cell therapies but requiring compatibility assessment.

References

1. Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nature Medicine (2023).
2. Comparative single-cell transcriptional and proteomic atlas of clinical-grade injectable mesenchymal source tissues. Science Advances (2024).
3. Bone Marrow Aspirate Concentrate: Its Uses in Osteoarthritis. International Journal of Molecular Sciences (2020).
4. Bone Marrow Aspirate Concentrate versus Platelet Rich Plasma or Hyaluronic Acid for the Treatment of Knee Osteoarthritis. Medicina (2021).